

Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele

Authorised

- *Leptospira interrogans*, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
- *Leptospira interrogans*, serovar Canicola, strain C51, Inactivated
- Canine parvovirus, strain NL-35-D, Live
- Canine parainfluenza virus, strain NL-CPI-5, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine distemper virus, strain N-CDV, Live

Product identification

Medicine name:

Vanguard Plus 7, süstelahuse lüofilisaat ja lahusti koertele

Active substance:

Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated

Leptospira interrogans, serovar Canicola, strain C51, Inactivated

Canine parvovirus, strain NL-35-D, Live

Canine parainfluenza virus, strain NL-CPI-5, Live

Canine adenovirus 2, strain Manhattan, Live

Canine distemper virus, strain N-CDV, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
40.00 Hamster protective Dose 80% / 1.00 dose

Leptospira interrogans, serovar Canicola, strain C51, Inactivated
40.00 Hamster protective Dose 80% / 1.00 dose

Canine parvovirus, strain NL-35-D, Live
1000000.00 50% cell culture infectious dose / 1.00 dose

Canine parainfluenza virus, strain NL-CPI-5, Live
1000000.00 50% cell culture infectious dose / 1.00 dose

Canine adenovirus 2, strain Manhattan, Live
1585.00 50% cell culture infectious dose / 1.00 dose

Canine distemper virus, strain N-CDV, Live
1000.00 50% cell culture infectious dose / 1.00 dose

Pharmaceutical form:

Lyophilisate and solvent for solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AI02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Estonia

Available in:

Estonia

Package description:

Available only in Estonian

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

27/04/2004

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

State Agency Of Medicines

Authorisation number:

1254

Date of authorisation status change:

27/04/2004

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.